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In 222 patients, 741 venous coronary bypass grafts were studied 
angiographically early, at 1 year and at a late examination at >6.5 
years (mean 9.6) after operation; 565 of these grafts were also 
examined 5 years postoperatively. Grafts were graded for patency 
and disease considered to be atherosclerotic and for both extent 
and profile of lesions. 
Graft occlusion rates increased steadily from 8% early to 20% 
at 5, 41 % at 10 and 45% at > 11.5 years after operation. All grafts 
were considered free of atherosclerosis early, but disease appeared 
in 8% at 1 year, increasing to 38% at 5 and 75% at 10 years 
postoperatively. Increasing involvement of vessel wall area was 
associated with greater protrusion of lesions into the graft lumen. 
Diseased grafts became more so at subsequent examinations, with 
occlusion occurring in many. However, absence of disease had 
It is well known that the long-term fate of coronary bypass 
vein grafts is principally determined by graft atherosclerosis. 
We (1) previously reported angiographic features of this 
disease up to 5 years after operation. We now describe its 
appearance and progression in coronary bypass vein grafts 
from 6.5 to > 11.5 years postoperatively. As in our previous 
study, we used a grading system to define patency and 
atherosclerosis of 741 vein grafts studied consecutively. 
Methods 
Study patients and grafts. In this study, we included only 
those patients who had follow-up angiograms early and at 1 
year and >6.5 years after operation. One hundred sixty-four 
patients (565 grafts) were studied early (mean 0.96 months) 
and at 1 year (mean 12.84 months), 5 years (mean 60 months) 
and >6.5 years after operation. In addition, there were 51 
patients (176 grafts) studied early, at 1 year and at a remote 
time after operation. Two hundred thirty-seven grafts were 
studied at 7.5 years (mean 7.4), 403 at 10 years (mean 9.9) 61 
at 12.5 years (mean 12.7) and 40 later (mean 14.2 years) after 
operation. Thus, 741 grafts in 222 patients were studied 
From the Cardio-Pulmonary Unit, National Defence Medical Centre, 
Ottawa and the University of Ottawa Heart Institute, Ottawa, Ontario, 
Canada. 
Manuscript received July 2, 1990; revised manuscript received October 
31, 1990, accepted November 27, 1990. 
Address for reprints: Dr. Gerald M. FitzGibbon, Cardio-Pulmonary Unit, 
National Defence Medical Centre, Ottawa, Ontario, Canada KIA OK6. 
© 1991 by the American College of Cardiology 
little prognostic significance because diseased and abruptly oc-
cluded grafts were generated in those with healthy appearance at 
earlier examinations. For instance, 82 % of very diseased grafts at 
the 5 year study originated from normal grafts at 1 year and 73% 
of occluded grafts at 1 year had appeared normal early postoper-
atively. 
Of 590 patent grafts free of disease at 1 year, 30% were 
occluded at the late examination, 76% of those patent were 
diseased, 55% of these were diffusely diseased and 35% were 
>50% narrowed. Only 17 % of the original 590 patent grafts were 
healthy at this time. Bypass graft atherosclerosis severely limits 
the long-term utility of these grafts. It is suggested that the 
solution may lie in some powerful drug regimen. 
(J Am Coll CardioI1991;17:1075-80) 
early, after 1 year and in the course of a late examination 
;:::6.5 years after operation; the majority of grafts were also 
examined 5 years after operation. The interval from opera-
tion to the late examination ranged from 80 to 187 months 
(mean 116) (9.6 years). The study included angiographic 
examination of 25% of all grafts in patients surviving 6.5 
years after operation. The subjects were mainly military 
personnel, all men, ranging in age from 31 to 67 years (mean 
45.7). 
Operations. Preoperative and follow-up evaluation of the 
patients was done by the Cardio-Pulmonary Unit of the 
National Defence Medical Centre, Ottawa, Ontario, Canada, 
but operations were undertaken by five surgeons at the 
University of Ottawa Heart Institute, where patients usually 
remained for ::548 h after operation. All operations entailing 
coronary bypass surgery were included in the study (for 
example, bypass operations also involving other procedures 
such as valve replacement or ventricular aneurysm repair). 
There were 3.3 vein grafts/operation. Internal mammary 
grafts were excluded. As background information, we report 
a perioperative mortality rate of 1.7% for all 1,202 first 
coronary bypass operations and of 5.4% for all 149 reoper-
ations. In the larger group from which study patients were 
derived, 92.7% (824 of 889) of patients had survived 6.5 
years after operation. We (2) previously reported a periop-
erative myocardial infarction rate of7.8% (transmural 3.2%), 
Technical background. Saphenous vein was harvested 
with minimal manipUlation and, pending placement, was 
kept in normal saline solution containing 60 mg of papaver-
0735-1097/911$3.50 
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Table 1. Graft Patency Grading on Follow-Up Angiography 
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Early I Year 5 Years 7.5 Years Years > 11.5 Years 
Total grafts 741 741 565 237 403 101 
Graft grade 
A 631 (85) 608 (82) 428 (76) 109 (46) 211 (52) 40 (40) 
B 52 (7) 34 (5) 24 (4) 31 (13) 27 (7) 15 (15) 
A + B (patent) 683 (92) 642 (87) 452 (80) 140 (59) 238 (59) 55 (55) 
0 58 (8) 99 (13) 1I3 (20) 97 (41) 165 (41) 46 (45) 
Numbers in parentheses are percent. A = good patency; B = graft narrowed at some point to <50% of grafted artery; 0 graft occluded. 
ine/loo ml. Most bypass grafts had a single distal anastomo-
sis, but some were of the sequential type, our experience 
with these having been described elsewhere (3). Twenty-
eight percent of the grafts were to the anterior descending 
coronary artery, 20% to its diagonal branches, 28% to 
branches of the marginocircumflex trunk and 24% to the 
trunk or branches of the right coronary artery. At angiogra-
phy, grafts were selectively opacified, usually with a Judkins 
size 4 right coronary catheter, in at least four vertical planes 
ranging from 60° to the right of the mid-line to 90° to the left 
of the mid-line, sometimes with axial views. Catheterization 
was facilitated by graft loop markers placed on the aortic 
wall at operation. Grafts were usually demonstrated to be 
occluded by opacification of stumps, sometimes supple-
mented by collateral evidence in native selective coronary 
angiograms; rarely, proximal aortic-flood examinations were 
required. High resolution radiographic equipment was used 
for recording on 35 mm cinefilm at 60 frames/so 
Graft patency grading. We used the grading system pre-
viously reported (4) to define bypass graft patency. The 
proximal and distal anastomoses of the graft and the trunk 
were assessed separately and each assigned a letter: A 
(good), B (fair) or 0 (occluded). Grade B indicated stenosis 
reducing the lumen to <50% of the grafted artery. The grade 
for the entire graft was the lowest of the three site gradings. 
This was essentially a hemodynamic grading system. We 
used another method, previously described (1), to classify 
angiographic appearances we believed due to atherosclero-
sis. This provided more purely morphologic information. 
Category I indicated that the graft outline was completely 
smooth without any irregularity that might be due to disease; 
in category II grafts, <50% of the estimated surface area of 
the graft intima was irregular; category III grafts had >50% 
of the intima involved. To define this finding more precisely 
and perhaps add more prognostic value, we also classified 
the lesions into high profile or low profile types (that is, high 
or low rise, elevation or reliet) depending on whether they 
encroached> 50% or <50% on what was considered to be 
the normal graft lumen at that point. These grading systems, 
all based on the worst aspects of four-plane views, entailed 
use of an "eyeballing" technique. Great care was taken, 
however, to classify grafts as accurately as possible within 
the framework outlined. 
Results 
Graft occlusion. Graft occlusion rates early, at 1,5, 7.5, 
10 and> 11.5 years after operation (Table l) were 8%, 13%, 
20%,41%,41% and 45%, respectively. Grafts to the marg-
inocircumflex and right coronary arteries had a significantly 
lower patency rate at the late examination than did grafts to 
the anterior descending coronary artery and its diagonal 
branches (Table 2). Most of the grafts were graded A, with a 
small core of grade B grafts. It is of surgical importance that 
in the early postoperative studies, most (46 [89%] of 52) of 
the B gradings were assigned because of narrowing at the 
distal anastomosis. After 5 years, an increasing number of 
grade B grafts were so graded because of trunk stenosis 
associated with atherosclerosis. 
The 7.5 year phenomenon. The striking increase in B 
grades at 7.5 years, followed by a decrease at 10 years, 
prompts an explanation applicable to other values in the :.5 
year columns of Tables I and 3. We (5) have drawn attentIon 
to this phenomenon elsewhere. Our ideal follow-up practice 
is to perform angiography early and at I and 5 years and then 
every 5 years after coronary bypass operations. Practically 
all our patients have early angiograms and the majority are 
restudied at I year (1,4-6), but military/civilian career, 
geographic and other factors reduce the number examined at 
5 and 10 years after operation. Findings in a group of 
regularly examined, compliant and readily available patients 
are probably well represented in the 5 and 10 year columns 
ofTables 1 and 3. However, at 7.5 years (between 79 and 102 
months postoperatively), we examined patients presenting 
for a "clinical" rather than a "routine" reason, including a 
number of patients who presented ostensibly' 'late" for their 
Table 2. Vessels Grafted and Late Graft Occlusion 
Grafted Late Occlusion 
(%) (%) 
Left anterior descending (LAD) 28 34 
Diagonal branches of LAD 20 38 
Marginocircumfiex 28 49 
Right coronary 24 45 
Right and marginocircumfiex occlusion rates significantly different (p < 
0.05) from rates in left anterior descending and diagonal grafts. 
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Table 3. Bypass Graft Atherosclerosis on Follow-Up Angiography 
7.5 \0 
Early 1 Year 5 Years Years Years > 11.5 Years 
Patent grafts 683 642 452 140 238 55 
Not diseased (I) 683 (100) 590 (92) 278 (62) 25 (18) 60 (25) 11 (20) 
Diseased 
II 0 46 (7) 98 (22) 53 (38) 79 (33) 12 (22) 
III 0 6 (I) 76 (16) 62 (44) 99 (42) 32 (58) 
II + III 0 52 (8) 174 (38) 115 (82) 178 (75) 44 (80) 
Proportion of 0 3 (6) 24 (14) 43 (37) 62 (35) 21 (48) 
diseased grafts 
high profile 
Proportion of all 0 3 (0.5) 24 (5) 43 (31) 62 (26) 21 (38) 
patent grafts 
high profile 
Numbers in parentheses are percent. II = graft with <50% of the intima estimated diseased; III = graft with >50% of the intima estimated diseased; high 
profile = atheroma encroaching >50% on graft lumen. 
5 year studies but on close questioning were found to have 
new angina. The values in the 7.5 year column in Tables 1 
and 3 are thus weighted toward more extensive graft disease 
and a higher rate of graft occlusion. 
Graft disease. Early after operation, all grafts were con-
sidered to be free of atherosclerosis (Table 3). At 1 year, 92% 
of the grafts appeared smooth walled and the remainder had 
some irregularity of outline, involving >50% of the graft 
surface area in only a few cases. By 5 years, however, only 
62% of grafts had normal-appearing intima and almost 50% 
of the remaining grafts were considered to have atheroscle-
rosis involving >50% of the graft surface area. Five percent 
of the diseased grafts had high profile lesions reducing the 
size of the graft lumen by >50%. At 10 years, only 25% of 
the patent grafts were considered healthy, >50% of the 
diseased grafts were in category III and 35% of the diseased 
grafts had high profile lesions. Further deterioration was 
seen > 11.5 years after operation. Table 3 demonstrates 
proliferation of the lesions we believe to be due to athero-
sclerosis in the plane of the vessel wall and at the same time 
progressively rising from the intima to obstruct blood flow. 
At > 11.5 years after operation, the atherosclerotic process 
produced >50% luminal obstruction in almost 50% of the 
diseased grafts; at this time, slightly >50% of the grafts 
remained patent and 80% of these were diseased. 
Diseased graft prognosis. Our data confirm that the pres-
ence of atherosclerosis in a coronary bypass vein graft 
presages increasing disease in the future. In 12 of the 31 
instances, category II grafts in the 1 year study became 
category III grafts at 5 years, and 3 other grafts became 
occluded. Similarly, of 33 low profile lesions at the 1 year 
study 7 became high profile lesions at 5 years and 4 others 
were associated with graft occlusion. Between the 5 year 
study and the late examination, 55 of 98 category II grafts 
became category III grafts and 27 became occluded. Like-
wise, of 76 category III grafts at the 5 year study, 41 were 
occluded at the late examination. Of 150 low profile lesions 
at the 5 year examination, 52 became high profile and 49 
showed graft occlusion at the late examination. Of 24 high 
profile lesions at the 5 year examination, 19 showed graft 
occlusion at the late examination. 
Healthy graft prognosis. The absence of disease in the 
course of any examination did not guarantee a similar state 
at the next study. For instance, 62 (82%) of 76 category III 
grafts at the 5 year examination were category I grafts at the 
1 year study. Sixty-eight (44%) of 155 category III grafts at 
the late examination were classified in category I at the 5 
year study. Of 193 category III grafts at the late examination, 
176 (91%) were classified as category I at the early study. 
Similarly, 30 (73%) of 41 occluded grafts at the 1 year study 
were classified as grade A category I grafts at the early 
examination and 26 (70%) of 37 occluded grafts at the 5 year 
study originated from grade A category I grafts at the 1 year 
examination. Ninety-one (53%) of 172 occluded grafts at the 
late examination originated from grade A category I grafts at 
the 1 year study. 
In summary, of 590 patent grafts free of disease at the 1 
year examination, 177 (30%) were occluded at the late 
examination; of the 413 patent grafts, 314 (76%) were dis-
eased; 174 (55%) of the unhealthy grafts were diffusely 
diseased and 111 (35%) of these were >50% narrowed; only 
99 (17%) of the original 590 patent grafts were healthy. 
Similarly, of 278 patent grafts free of disease at 5 years, 55 
(20%) were occluded at the late examination, 153 (69%) of 
the 223 patent grafts were diseased, 69 (45%) of unhealthy 
grafts were diffusely diseased and 43 (28%) of these were 
>50% narrowed; only 70 (25%) of the original 278 patent 
grafts free of disease at the 5 year study were healthy at the 
late examination. 
Discussion 
Graft occlusion. Early after operation, coronary bypass 
grafts may become occluded by thrombus, frequently form-
ing at the distal graft-coronary anastomosis. It is probably 
highly significant that 89% of our early postoperative B 
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grades were assigned to grafts with distal anastomosis de-
fects. However, these technical factors are not alone of 
importance. Almost 75% of grafts found occluded at the 1 
year study had been angiographically normal early after 
operation. Intimal disruption, perhaps associated with myo-
intimal hyperplasia, and localized platelet dysfunction may 
lead to the formation of an occlusive thrombus. These events 
are poorly understood. There is no doubt, however, that 
later in their course coronary bypass grafts become subject 
to atherosclerosis (7-15). There are proliferation of smooth 
muscle cells, intimal damage, the complex interaction of 
endothelium and locally deposited platelets and the accumu-
lation of lipids in "foam cells" (11-13). Plaques form and 
assume different compositions depending on the degree of 
fibrosis, the extent of lipid deposit, the addition of thrombus 
and the occurrence of calcification. Localized aneurysm 
formation may take place, invariably associated with ad-
vanced atherosclerosis. The degree of disease in the bypass 
grafts does not appear to parallel the progress of atheroscle-
rosis in the native coronary arteries (15). Thrombus may 
accumulate slowly or after an abrupt "plaque accident" 
similar to that occurring in a coronary artery (16). Athero-
embolism may occur spontaneously or lethally at reopera-
tion (17). The final event is graft occlusion. 
Autopsy studies and examination of grafts removed at 
coronary bypass reoperations attest that with the passage of 
time atherosclerosis becomes very common in these grafts. 
Neitzel et al. (12) observed the disease process in 71% of 
grafts removed between 6 and 12 years after operation. We 
believe that we are observing this process at various stages 
in our follow-up angiograms. 
Graft patency grading. Our A, Band 0 patency grading 
seems noncontroversial. The A and 0 grades can be as-
signed easily; a B grade presents some problems. Grafts are 
graded B because of stenosis of the proximal or distal 
anastomosis or in the trunk of the graft reducing the size of 
the lumen to <50% of the grafted artery. We believe that we 
have validated the honesty of the B grading (graft lumen 
<50% of the grafted artery). In a large series, we (4) 
demonstrated that 24% of early grade B grafts were occluded 
at 1 year and that 39% remained the same; however, only 6% 
of grade A grafts went on to occlusion and 4% became grade 
B (p < 0.0005). 
Graft disease grading. Diagnosing and grading athero-
sclerosis in coronary bypass graft angiograms involve some 
speculation. We recognize that we have no systematic 
pathologic corroboration of our angiographic findings. Lytle 
et al. (10) indicated that myointimal hyperplasia and throm-
bus present diagnostic pitfalls. Solymoss et al. (13) described 
late thrombosis in vein grafts associated with nonatheroscle-
rotic intimal hyperplasia, although this most often accompa-
nies atherosclerosis. Nevertheless, we believe that ascrip-
tion of atherosclerosis to coronary bypass graft angiograms 
showing what we have described as category I, II or III 
grafts with high or low profile lesions is in accord with 
pathologic and angiographic opinion (7-31). Grondin et al. 
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(26) described these angiographic findings, including use of 
the terms "irregular wall," "plaque," "conventional steno-
sis," "spur diaphragm" and "cauliftower." These features 
may be seen in native vessel coronary angiograms. 
In our sequential studies, as might be expected to occur 
with atherosclerotic disease, proliferation of lesions in the 
graft's mural plane is progressively associated with their 
elevation from the vessel wall to produce luminal obstruc-
tion. We believe that our grading system is justifiable in 
describing what we consider to be atherosclerosis in coro-
nary bypass vein grafts. 
Effects of drugs. For >20 years, we have given to our 
patients with coronary disease medications affecting the 
behavior of platelets for reasons arising from Duguid's 
encrustation theory (32) of the development of atherosclero-
sis. These drugs have usually been aspirin and dipyridamole, 
sulfinpyrazone occasionally being substituted for the former. 
Administration of aspirin but not dipyridamole was discon-
tinued for 1 week before operation, sulfinpyrazone being 
substituted, but treatment with both aspirin and dipyrida-
mole was started again 1 to 3 days after operation. The 
beneficial effect of these two agents on early and late 
coronary bypass graft patency has been demonstrated by 
Chesebro et al. (33,34). We have not had a control series. 
Use of these medications is not the topic of this report, but 
attention must nevertheless be drawn to their administra-
tion. 
Graft disease and bypass grafting. An incidence of late 
coronary venous bypass graft atherosclerotic stenosis and 
occlusion generally similar to ours has been reported by 
others, notably in major series from the Montreal Heart 
Institute (8,15,31) and the Cleveland Clinic (10); our results 
confirm theirs. We demonstrated a relentless progression of 
disease in coronary bypass vein grafts with increasing large 
areas of intimal involvement and steady growth in the 
volume oflesions, graft occlusion being the end result. At 10 
years after operation, 41 % of our bypass grafts were oc-
cluded and 75% of those that were not occluded were 
diseased. Furthermore, we demonstrated in our angiograms 
that graft atherosclerosis behaves in a capricious manner. 
Bypass graft disease surely begets disease-there is nothing 
as atherogenic as atheroma-but a "healthy" appearance 
does not perpetuate itself. Graft occlusion, the final insult, is 
sometimes the end stage of atherosclerosis and its compli-
cations and at other times occurs for no obvious reason. 
What then is the continuing long-term utility of the 
saphenous vein coronary bypass graft? Our limited experi-
ence with other large bore conduits, arm vein, umbilical vein 
and synthetic material, has been disappointing, although a 
single Gore-Tex right coronary bypass graft remained patent 
at 1 year but was occluded at 5 years after operation. Our 
patency rates are somewhat better for internal mammary 
artery grafts than for vein grafts. In a recent unpublished 
series of 169 consecutive internal mammary artery grafts 
opacified early after operation, the patency rate was 96% but 
there was a 10% incidence of grade B grafts, almost all 
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associated with distal anastomotic defects. In the long term, 
however, the internal mammary artery remains free of 
atherosclerosis and the effect of its use on late mortality has 
been demonstrated (35). Nevertheless, there are only two 
internal mammary arteries and the right vessel is anatomi-
cally limited in its reach. The right gastroepiploic artery has 
been used successfully for coronary bypass grafting (36,37), 
but its dissection complicates the coronary bypass proce-
dure and it has not yet become widely used. Certainly, if it 
were not for graft atherosclerosis, the saphenous vein, which 
is easily accessible and plentiful, would be the ideal conduit 
for coronary bypass grafting. 
Causes of vein graft atherosclerosis. Campeau et al. (31) 
demonstrated an association between elevated levels of 
certain blood lipoproteins and atherosclerosis in coronary 
bypass grafts; others (38) have narrowed the field of search. 
We (39) demonstrated a statistically significant relation be-
tween atherosclerosis of coronary venous bypass grafts and 
smoking. There are undoubtedly many other factors, ranging 
from intimal damage done at the time of operation to the 
long-term effects of "arterializing" a vein, to say nothing of 
possible autoimmune or even more remote genetic consid-
erations. The reader is referred to the excellent editorial 
review by Grondin (11). 
The future. Meticulous handling of the venous conduit at 
operation and exacting surgical technique are essential, 
particularly for early success, but these are probably not 
sufficient factors to prevent atherosclerosis in the long term. 
The high cost in lives and money of coronary bypass 
reoperations militates against their use in dealing with the 
problem of saphenous vein graft atherosclerosis. Control of 
conventional risk factors, particularly diet and smoking, is 
mandated by the available evidence. Yet this may not be 
enough. We have assiduously prescribed agents modifying 
the behavior of platelets from the beginning of our experi-
ence with coronary bypass grafting, but we doubt that our 
long-term results can be considered confirmation of their 
efficacy in preventing or retarding atherosclerosis. Perhaps 
our results would have been much worse if we had not used 
these drugs. Newer medications may save the day. These 
include drugs to normalize dyslipidemias (40) and the cal-
cium channel blockers (41) reportedly used with some suc-
cess. We await the advent of the agent or the technique that 
will restore to the saphenous vein coronary bypass graft its 
once great promise. 
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